Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

GenAssist Therapeutics

Company Type: Therapeutic development

Main focus: Developing optimised bas-editing therapies for Duchenne muscular dystrophy

Company stage: Pre-clinical

Diseases: Duchenne muscular dystrophy

Genome-editing tool: TAM base editing

Funding stage: Series A

Location: Suzhou, Jiangsu, China

Website: genassisttx.com

Pipeline: genassisttx.com/pipeline/

Partners:

GenAssist Therapeutics is a biotech company based in China focusing on the development of advanced and optimised base-editing therapeutics to treat Duchenne muscular dystrophy (DMD) and eventually other diseases. The company utilises Targeted AID-mediated mutagenesis (TAM) base-editing technology to modify target DNA. The company is currently investigating several different editing outcomes including exon skipping, activating alternative splice sites, and editing splicing regulatory elements.

Tags

HashtagGenAssist Therapeutics

Company: GenAssist Therapeutics
close
Search CRISPR Medicine